A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), ...

Close to 60% of all patients with VHL will develop RCC or renal cysts. A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC ...

A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or ...

Survivors of COVID-19 may be at risk of developing spontaneous osteonecrosis of the jaw, according to a case series published June 14 in BMC Infectious Diseases. These are believed to be the first ...

Absorption profile, safety, and tolerability of a 200 μg dose of fentanyl buccal tablet (FBT) in opioid-tolerant cancer patients with or without oral mucositis No significant financial relationships ...

Philadelphia, PA - A review of jaw osteonecrosis as a recently described adverse effect of bisphosphonate therapy in the May 16, 2006 issue of the Annals of Internal Medicine concludes that most cases ...

Cancer patients taking bisphosphonate drugs for the prevention of fractures appear more likely to develop jaw disease than patients who do not take the drugs, according to an analysis of records from ...

A team of scientists from UCLA's School of Dentistry, Jane and Jerry Weintraub Center for Reconstructive Biotechnology, School of Public Health and David Geffen School of Medicine has performed ...

In a move that may prompt millions of women to rethink their use of popular bone-building drugs, the Food and Drug Administration (FDA) published an analysis that suggested caution about long-term use ...

Please provide your email address to receive an email when new articles are posted on . Patients in the pre-collapse stages of post-traumatic osteonecrosis of the femoral head may receive safe and ...